CN115895899A - Freeze-drying protective agent and freeze-drying process of fecal fungi - Google Patents
Freeze-drying protective agent and freeze-drying process of fecal fungi Download PDFInfo
- Publication number
- CN115895899A CN115895899A CN202211448984.0A CN202211448984A CN115895899A CN 115895899 A CN115895899 A CN 115895899A CN 202211448984 A CN202211448984 A CN 202211448984A CN 115895899 A CN115895899 A CN 115895899A
- Authority
- CN
- China
- Prior art keywords
- freeze
- drying
- lyoprotectant
- fecal
- protective agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004108 freeze drying Methods 0.000 title claims abstract description 84
- 239000003223 protective agent Substances 0.000 title claims abstract description 46
- 230000002550 fecal effect Effects 0.000 title claims abstract description 37
- 241000233866 Fungi Species 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 14
- 230000008569 process Effects 0.000 title claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 46
- 239000007788 liquid Substances 0.000 claims abstract description 39
- 210000003608 fece Anatomy 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 19
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 16
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 16
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 13
- 235000020183 skimmed milk Nutrition 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 8
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 7
- 239000005642 Oleic acid Substances 0.000 claims description 7
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000012792 lyophilization process Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 244000234623 Coprinus comatus Species 0.000 description 3
- 235000004439 Coprinus comatus Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- 235000003934 Abelmoschus esculentus Nutrition 0.000 description 1
- 241000222511 Coprinus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a freeze-drying protective agent and a freeze-drying process of fecal fungi. The freeze-drying protective agent and the freeze-drying process of the fecal bacteria provided by the invention can protect the activity of bacteria liquid extracted from feces and effectively improve the freeze-drying survival rate of the fecal bacteria flora.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a freeze-drying protective agent and a freeze-drying process of fecal bacteria.
Background
The fecal strain transplantation is to transplant functional flora in the feces of healthy people into the gastrointestinal tract of a patient to reconstruct the intestinal flora of the patient and realize the diagnosis and treatment of intestinal tract and parenteral diseases. At present, the fecal strain transplantation technology is mainly an instrument intervention mode, needs to be transplanted for multiple times, and has higher technical requirements. Meanwhile, the prepared fecal strain sample has short storage time at room temperature, and can cause certain pain to patients, so that the application of the fecal strain sample is limited.
The preparation of the coprinus comatus freeze-dried powder can avoid the intervention of instruments in a transplantation mode, reduce the volume and weight of administration and facilitate transportation and storage.
Since the drying object is an active microorganism, the microorganism is more fragile during the drying process and more sensitive to the drying conditions than other non-living active substances (such as proteins, enzymes, etc.). Therefore, the freeze-drying process of the microorganisms is more difficult, and the most common freeze-drying of the lactic acid bacteria and the probiotics requires a protective agent to be added when the microorganisms are freeze-dried, besides common fillers and excipients.
CN105602875A discloses a protective agent for storing lactobacillus lyophilized powder at normal temperature, which comprises skimmed milk powder 2-4wt%, sodium glutamate 2-4wt%, trehalose 5-8wt%, maltitol 2-5wt% and polydextrose 12-18wt%.
CN110964640A discloses a freeze-drying protective agent for protecting thallus of a fermentation strain, which comprises skim milk powder, tamarind seed polysaccharide, polydextrose and water.
Unlike traditional lactic acid bacteria and probiotics, the flora from feces is not a single well-defined strain or species, but a complex group of flora with a large variety of contents. Compared with lactic acid bacteria and probiotics, the anaerobic degree of microorganisms in the fecal flora is higher, and many of the strains are sensitive to environmental conditions and difficult to survive in a laboratory environment for a long time. Therefore, freeze-drying is an important means for preserving and producing fecal flora, and the search for suitable freeze-drying protective agents to protect the stability of flora in feces is an important technical barrier to the realization of human intestinal flora industrialization.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a freeze-drying protective agent and a freeze-drying process of fecal bacteria. The freeze-drying protective agent provided by the invention can protect the activity of bacteria liquid extracted from excrement and effectively improve the freeze-drying survival rate of the fecal bacteria flora.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides a lyoprotectant, wherein the raw materials for preparing the lyoprotectant comprise a saccharide substance and a high-molecular protectant, and the saccharide substance comprises a combination of xylooligosaccharide, trehalose and mannitol.
In the invention, the raw materials for preparing the lyoprotectant comprise 10-20 parts (for example, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts and the like) of carbohydrate substances and 5-10 parts (for example, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts and the like) of high-molecular protectant according to parts by weight.
Preferably, the mass ratio of the xylo-oligosaccharide, the trehalose and the mannitol is (5-10): (3-8): (1-5);
wherein "5-10" can be 5, 6, 7, 8, 9, 10, etc.;
"3-8" can be 3, 4, 5, 6, 7, 8, etc.;
"1-5" can be 1, 2, 3, 4, 5, etc.
Preferably, the polymeric protectant comprises skim milk powder.
In the invention, the raw materials for preparing the lyoprotectant also comprise any one or combination of at least two of unsaturated fatty acid, amino acid or salt.
Preferably, the raw materials for preparing the lyoprotectant also comprise unsaturated fatty acid, amino acid and salt.
Preferably, the raw materials for preparing the lyoprotectant also comprise, by weight, 0.005-0.015 parts (for example, 0.005 parts, 0.007 parts, 0.009 parts, 0.011 parts, 0.013 parts, 0.015 parts and the like), 1-3 parts (for example, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts and the like) of an unsaturated fatty acid, and 0.1-1 part (for example, 0.1 part, 0.3 part, 0.5 part, 0.7 part, 0.9 part, 1 part and the like) of a salt.
Preferably, the lyoprotectant further includes a solvent including, by weight, 90-110 parts of water (e.g., 90 parts, 93 parts, 96 parts, 99 parts, 103 parts, 106 parts, 109 parts, 110 parts, etc.).
In the present invention, the unsaturated fatty acid includes oleic acid.
Preferably, the amino acid comprises poly-gamma-glutamic acid.
Preferably, the salt comprises sodium alginate.
In a second aspect, the invention provides a use of the lyoprotectant according to the first aspect in the preparation of a freeze-dried product of fecal bacteria.
The fecal bacteria in the present invention refers to bacteria obtained by extracting human feces through a fecal bacteria separation system.
In a third aspect, the invention provides a coprophilous fungus freeze-drying process, wherein the coprophilous fungus is freeze-dried by adopting the freeze-drying protective agent of the first aspect.
In the present invention, the lyophilization process specifically comprises the following steps: and mixing the fecal strain liquid with a freeze-drying protective agent, and then carrying out freeze-drying to obtain freeze-dried fecal strains.
In the invention, the fecal bacteria liquid is obtained by extracting human feces through a fecal bacteria separation system;
preferably, the solid-liquid ratio of the fecal strain liquid to the freeze-drying protective agent is 1 (1-1.5);
wherein "1-1.5" may be 1, 1.1, 1.2, 1.3, 1.4, 1.5, etc.
The optimal mixing ratio of the bacteria liquid to the freeze-drying protective agent is w: v = 1.2.
In the present invention, after the freeze-drying, a post-treatment is further included, the post-treatment including the steps of: and (3) crushing and sieving the freeze-dried fecal fungi obtained after freeze drying to obtain the fecal fungi freeze-dried powder.
Preferably, the pulverization is carried out in an environment having a humidity of 30% or less (for example, 28%, 25%, 21%, 15%, 13%, 10%, 8%, 5%, 3%, etc. may be used).
Preferably, the screen is a 100-300 mesh screen (e.g., 100 mesh, 130 mesh, 160 mesh, 190 mesh, 230 mesh, 260 mesh, 290 mesh, 300 mesh, etc.).
In the invention, the coprophilous fungi freeze-dried powder can be subpackaged in capsules to prepare oral capsules, the effect of the oral capsules is not inferior to that of a colonoscope transplantation mode, the psychological barrier of patients receiving coprophilic fungi transplantation is eliminated, and the uncomfortable physiological reaction brought in the treatment process is eliminated.
As a preferable technical scheme of the invention, the preparation method of the coprinus freeze-dried powder capsule comprises the following steps:
(1) Separation: human excrement is obtained, and bacteria liquid is extracted through an excrement and bacteria separation system.
(2) Freeze-drying: uniformly mixing the obtained bacterial liquid and a freeze-drying protective agent according to the solid-liquid ratio of 1 (1-1.5), and freeze-drying to obtain freeze-dried bacterial liquid;
(3) Crushing: crushing the freeze-dried bacterial liquid in an environment with the humidity of below 30%, and sieving the crushed bacterial liquid by a 100-300-mesh sieve to obtain bacterial liquid freeze-dried powder;
(4) Filling: and subpackaging the bacterium liquid freeze-dried powder into capsules to prepare the coprinus comatus freeze-dried powder capsules.
In the present invention, the freeze-drying specifically comprises the steps of:
compared with the prior art, the invention has the following beneficial effects:
the freeze-drying protective agent and the freeze-drying process of the fecal bacteria provided by the invention can protect the activity of bacteria liquid extracted from feces and effectively improve the freeze-drying survival rate of fecal bacteria flora.
Drawings
FIG. 1 is an appearance diagram of live bacteria and dead bacteria.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Xylo-oligosaccharides were purchased from gumbo food flagship stores in the following examples.
Example 1
The embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant comprises the following steps: 8% (W/V) of xylo-oligosaccharide, 5% (W/V) of trehalose, 3% (W/V) of mannitol, 7% (W/V) of skimmed milk powder, 2% (W/V) of poly gamma-glutamic acid, 0.5% (W/V) of sodium alginate and 0.01% (W/V) of oleic acid are mixed to obtain the freeze-drying protective agent, and the solvent of the freeze-drying protective agent is water.
Example 2
The present embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant includes the following steps: mixing 5% (W/V) xylo-oligosaccharide, 7% (W/V) trehalose, 2% (W/V) mannitol, 5% (W/V) skimmed milk powder, 3% (W/V) poly gamma-glutamic acid, 0.3% (W/V) sodium alginate and 0.008% (W/V) oleic acid to obtain the freeze-drying protective agent, wherein the solvent of the freeze-drying protective agent is water.
Example 3
The embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant comprises the following steps: mixing 10% (W/V) xylo-oligosaccharide, 3% (W/V) trehalose, 5% (W/V) mannitol, 10% (W/V) skimmed milk powder, 3% (W/V) poly gamma-glutamic acid, 0.8% (W/V) sodium alginate and 0.012% (W/V) oleic acid to obtain the freeze-drying protective agent, wherein the solvent of the freeze-drying protective agent is water.
Example 4
The embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant comprises the following steps: mixing 8% (W/V) of sucrose, 5% (W/V) of trehalose, 3% (W/V) of mannitol and 7% (W/V) of skimmed milk powder to obtain the freeze-drying protective agent, wherein the solvent of the freeze-drying protective agent is water.
Example 5
The embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant comprises the following steps: mixing 8% (W/V) xylo-oligosaccharide, 5% (W/V) trehalose, 3% (W/V) mannitol, 0.5% (W/V) sodium bicarbonate and 7% (W/V) skimmed milk powder to obtain the freeze-drying protective agent, wherein the solvent of the freeze-drying protective agent is water.
Example 6
The embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant comprises the following steps: and (3) mixing 8% (W/V) of xylo-oligosaccharide, 5% (W/V) of trehalose, 3% (W/V) of mannitol and 7% (W/V) of skimmed milk powder to obtain the freeze-drying protective agent, wherein the solvent of the freeze-drying protective agent is water.
Example 7
The embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant comprises the following steps: mixing 8% (W/V) of soybean polysaccharide, 5% (W/V) of trehalose, 3% (W/V) of mannitol, 7% (W/V) of skimmed milk powder, 2% (W/V) of lysine, 0.5% (W/V) of sodium alginate and 0.01% (W/V) of oleic acid to obtain the freeze-drying protective agent, wherein the solvent of the freeze-drying protective agent is water.
Example 8
The present embodiment provides a lyoprotectant, and a preparation method of the lyoprotectant includes the following steps: mixing 8% (W/V) xylo-oligosaccharide, 5% (W/V) trehalose, 3% (W/V) mannitol, 7% (W/V) skimmed milk powder, 2% (W/V) lysine, 0.5% (W/V) sodium alginate and 0.01% (W/V) oleic acid to obtain the freeze-drying protective agent, wherein the solvent of the freeze-drying protective agent is water.
Example 9
This example provides a lyoprotectant, which is different from example 1 only in that poly-gamma-glutamic acid is replaced with glycine at the same content, and the other preparation methods are the same as example 1.
Comparative example 1
This example provides a lyoprotectant, which is different from example 1 only in that it does not contain xylooligosaccharide, the content of trehalose is increased to 10% (W/V), the content of mannitol is increased to 6% (W/V), and other preparation methods are the same as example 1.
Comparative example 2
This example provides a lyoprotectant, which is different from example 1 only in that, without trehalose, the content of xylooligosaccharide is increased to 11.6% (W/V) and the content of mannitol is increased to 4.4% (W/V), and other preparation methods are the same as example 1.
Comparative example 3
This example provides a lyoprotectant, which is different from example 1 only in that, without mannitol, the content of xylooligosaccharide is increased to 9.8% (W/V) and the content of trehalose is increased to 6.2% (W/V), and other preparation methods are the same as example 1.
Application example 1
The application example provides coprophila freeze-dried powder, and the preparation method of the coprophila freeze-dried powder comprises the following steps:
(1) Separation: human excrement is obtained, and bacteria liquid is extracted through an excrement and bacteria separation system.
(2) Freeze-drying: uniformly mixing the obtained bacterial liquid and the freeze-drying protective agent provided in the embodiment 1 according to w: v = 1.2, and freeze-drying to obtain freeze-dried bacterial liquid;
(3) Crushing: crushing the freeze-dried bacterial liquid in an environment with the humidity of 25%, and sieving the crushed bacterial liquid with a 100-mesh sieve to obtain freeze-dried bacterial liquid powder;
wherein, in the step (2), the freeze drying specifically comprises the following steps:
| segment number | Time (h) | Temperature (. Degree. C.) |
| 1 | 4 | -40.0 |
| 2 | 12 | -30.0 |
| 3 | 4 | -20.0 |
| 4 | 4 | 0.0 |
| 5 | 5 | 10.0 |
| 6 | 3 | 15.0 |
| 7 | 2 | 17.0 |
| 8 | 8 | 25.0 |
| 9 (end segment) | 1 | 30.0 |
。
Application example 2
The application example provides coprophila freeze-dried powder, and the preparation method of the coprophila freeze-dried powder comprises the following steps:
(1) Separation: human excrement is obtained, and bacteria liquid is extracted through an excrement and bacteria separation system.
(2) Freeze-drying: uniformly mixing the obtained bacterial liquid and the freeze-drying protective agent provided in the embodiment 2 according to w: v = 1.1, and freeze-drying to obtain freeze-dried bacterial liquid;
(3) Crushing: crushing the freeze-dried bacterial liquid in an environment with the humidity of 22%, and sieving the crushed bacterial liquid with a 300-mesh sieve to obtain freeze-dried bacterial liquid powder;
wherein, in the step (2), the freeze drying specifically comprises the following steps:
application example 3
The application example provides coprophila freeze-dried powder, and the preparation method of the coprophila freeze-dried powder comprises the following steps:
(1) Separation: human excrement is obtained, and bacteria liquid is extracted through an excrement and bacteria separation system.
(2) Freeze-drying: uniformly mixing the obtained bacterial liquid with the freeze-drying protective agent provided by the embodiment 3 according to the w: v = 1.3, and then freezing and drying to obtain freeze-dried bacterial liquid;
(3) Crushing: crushing the freeze-dried bacterial liquid in an environment with the humidity of 20%, and sieving with a 200-mesh sieve to obtain freeze-dried bacterial liquid powder;
wherein, in the step (2), the freeze drying specifically comprises the following steps:
application examples 4 to 9
Application examples 4 to 9 respectively provide a coprophilous fungi freeze-dried powder, and the difference from the application example 1 is only that the freeze-drying protective agent provided in the example 1 is replaced by the freeze-drying protective agents provided in the examples 4 to 9 respectively.
Application example 10
The application example provides coprophilous fungus freeze-dried powder, and the difference from the application example 1 is only that in the step (2), the freeze-drying specifically comprises the following steps:
| segment number | Time (h) | Temperature (. Degree.C.) |
| 1 | 4 | -40.0 |
| 2 | 16 | -30.0 |
| 3 | 4 | 0.0 |
| 4 | 5 | 10.0 |
| 5 | 3 | 15.0 |
| 6 | 2 | 17.0 |
| 7 | 8 | 25.0 |
| 8 (end segment) | 1 | 30.0 |
。
Application example 11
The application example provides coprophilous fungus freeze-dried powder, and the difference from the application example 1 is only that in the step (2), the freeze-drying specifically comprises the following steps:
application example 12
The application example provides coprophila freeze-dried powder, and the difference from the application example 1 is only that in the step (2), the freeze-drying specifically comprises the following steps:
| segment number | Time (h) | Temperature (. Degree.C.) |
| 1 | 4 | -32 |
| 2 | 12 | -20 |
| 3 | 4 | -10 |
| 4 | 4 | 6 |
| 5 | 5 | 15 |
| 6 | 3 | 18 |
| 7 | 2 | 18 |
| 8 | 8 | 28 |
| 9 (end segment) | 1 | 37 |
。
Comparative application examples 1 to 3
Comparative application examples 1 to 3 respectively provide a coprophila freeze-dried powder, and the difference from the application example 1 is only that the freeze-drying protective agent provided in the example 1 is replaced by the freeze-drying protective agents provided in the comparative examples 1 to 3 respectively.
Test example
Survival rate testing
Testing a sample: the coprophila freeze-dried powder provided in application examples 1-12 and comparative application examples 1-3.
The test method comprises the following steps:
(1) Freeze-drying survival rate test
The test method comprises the following steps: diluting the bacterial liquid by 10 times or taking 50mg of bacterial powder into a 1.5mL EP tube, adding 1mL of sterile physiological saline for full dissolution, and mixing the diluted bacterial liquid with 0.4% trypan blue according to the proportion of 9. Counting was performed using a hemocytometer. Bacteria were counted diagonally in the top left, bottom left, top right and bottom right 4 squares using a 16 x 25 counting chamber. During counting, when meeting the bacteria on the square line, counting according to the principle of 'recording up but not recording down, recording left but not recording right'. The number of live bacteria (clear) and dead bacteria (black) were counted separately for calculating the survival rate of the bacteria (appearance of live and dead bacteria as shown in FIG. 1). After the original data are obtained, an average value is taken, and calculation is performed according to the following mode: average 16 x 10000, resulting in the corresponding total number of bacteria. And (4) counting result N of bacterial powder dissolution, (N/weighed weight) to obtain a final counting result.
Freeze-drying survival (%) = (number of live bacteria before freeze-drying/number of live bacteria after freeze-drying) × 100%.
(2) Viability test after 30 days of storage at-20 ℃
The test method comprises the following steps: the fecal strain lyophilized powders provided in application examples 1 to 12 and comparative application examples 1 to 3 were separately packed in a centrifuge tube, and after storage at-20 ℃ for 30 days, the survival rate was calculated.
Survival (%) after 30 days storage at 20 = (-number of viable bacteria after 30 days storage at 20 ℃/number of viable bacteria before storage) × 100%.
The test results are shown in table 1 below:
TABLE 1
As can be seen from the data in Table 1, the freeze-drying protective agent and the drying process provided by the invention can improve the survival rate of fecal bacteria. Wherein the viable count of the coprinus comatus freeze-dried powder provided by the application example 1 can reach 7.97 multiplied by 10 11 CFU/g. Various components in the freeze-drying protective agent are matched with each other, and have synergistic effect, so that the activity of the fecal bacteria can be improved.
The applicant states that the present invention is illustrated by the above examples of the process of the present invention, but the present invention is not limited to the above process steps, i.e. it is not meant that the present invention must rely on the above process steps to be carried out. It will be apparent to those skilled in the art that any modification of the present invention, equivalent substitutions of selected materials and additions of auxiliary components, selection of specific modes and the like, which are within the scope and disclosure of the present invention, are contemplated by the present invention.
Claims (10)
1. The lyoprotectant is characterized in that raw materials for preparing the lyoprotectant comprise a saccharide substance and a high-molecular protectant, wherein the saccharide substance comprises a combination of xylooligosaccharide, trehalose and mannitol.
2. The lyoprotectant according to claim 1, wherein the raw materials for preparing the lyoprotectant comprise, by weight, 10-20 parts of carbohydrate and 5-10 parts of polymeric protectant;
preferably, the mass ratio of the xylo-oligosaccharide, the trehalose and the mannitol is (5-10): (3-8): (1-5);
preferably, the polymeric protectant comprises skim milk powder.
3. The lyoprotectant according to claim 1 or 2, wherein the raw materials for preparing the lyoprotectant further comprise any one or a combination of at least two of unsaturated fatty acid, amino acid or salt;
preferably, the raw materials for preparing the lyoprotectant also comprise unsaturated fatty acid, amino acid and salt;
preferably, the raw materials for preparing the freeze-drying protective agent also comprise 0.005-0.015 part of unsaturated fatty acid, 1-3 parts of amino acid and 0.1-1 part of salt in parts by weight;
preferably, the lyoprotectant further comprises a solvent, wherein the solvent comprises 90-110 parts by weight of water.
4. The lyoprotectant of claim 3, wherein said unsaturated fatty acid comprises oleic acid;
preferably, the amino acid comprises poly-gamma-glutamic acid;
preferably, the salt comprises sodium alginate.
5. Use of a lyoprotectant according to any one of claims 1-4 in the preparation of a lyophilized fecal product.
6. A freeze-drying process for coprophilous fungi, which is characterized in that the coprophilous fungi is freeze-dried by using the freeze-drying protective agent of any one of claims 1 to 4.
7. Lyophilization process according to claim 6, characterized in that it comprises in particular the steps of: and mixing the fecal strain liquid with a freeze-drying protective agent, and then carrying out freeze-drying to obtain freeze-dried fecal strains.
8. The lyophilization process according to claim 6 or 7, wherein the fecal bacteria liquid is obtained by extracting human feces through a fecal bacteria separation system;
preferably, the solid-liquid ratio of the fecal strain liquid to the freeze-drying protective agent is 1 (1-1.5).
9. Lyophilization process according to claim 7 or 8, characterized in that it further comprises a post-treatment after said lyophilization, said post-treatment comprising the following steps: crushing and sieving freeze-dried fecal fungi obtained after freeze drying to obtain fecal fungi freeze-dried powder;
preferably, the pulverization is carried out in an environment having a humidity of 30% or less;
preferably, the screening is performed with a 100-300 mesh screen.
10. Lyophilization process according to any one of claims 7 to 9, characterized in that said lyophilization comprises in particular the steps of:
。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211448984.0A CN115895899A (en) | 2022-11-18 | 2022-11-18 | Freeze-drying protective agent and freeze-drying process of fecal fungi |
| PCT/CN2023/096011 WO2024103667A1 (en) | 2022-11-18 | 2023-05-24 | Lyoprotectant and lyophilization process of fecal microbiota |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211448984.0A CN115895899A (en) | 2022-11-18 | 2022-11-18 | Freeze-drying protective agent and freeze-drying process of fecal fungi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115895899A true CN115895899A (en) | 2023-04-04 |
Family
ID=86480935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211448984.0A Pending CN115895899A (en) | 2022-11-18 | 2022-11-18 | Freeze-drying protective agent and freeze-drying process of fecal fungi |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115895899A (en) |
| WO (1) | WO2024103667A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024103667A1 (en) * | 2022-11-18 | 2024-05-23 | 上海宝藤生物医药科技股份有限公司 | Lyoprotectant and lyophilization process of fecal microbiota |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018272048B2 (en) * | 2017-05-26 | 2024-04-04 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| CN108277178B (en) * | 2018-02-02 | 2021-07-02 | 山东凤凰生物有限公司 | Industrial high-density mixed fermentation culture method for bifidobacteria and lactobacilli and bacteria powder embedding method |
| CN114196543A (en) * | 2021-11-25 | 2022-03-18 | 天津大学浙江绍兴研究院 | Fecal strain cryoprotectant and application thereof in fecal strain preservation |
| CN115895899A (en) * | 2022-11-18 | 2023-04-04 | 上海宝藤生物医药科技股份有限公司 | Freeze-drying protective agent and freeze-drying process of fecal fungi |
-
2022
- 2022-11-18 CN CN202211448984.0A patent/CN115895899A/en active Pending
-
2023
- 2023-05-24 WO PCT/CN2023/096011 patent/WO2024103667A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024103667A1 (en) * | 2022-11-18 | 2024-05-23 | 上海宝藤生物医药科技股份有限公司 | Lyoprotectant and lyophilization process of fecal microbiota |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024103667A1 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102827796B (en) | Lactobacillus plantarum with cadmium removing function and usage thereof | |
| CN108208853A (en) | A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method | |
| CN111662850B (en) | Lactobacillus paracasei capable of relieving alcoholic intestinal injury and application thereof | |
| CN107164274B (en) | Lactobacillus composite microbial agent and preparation method and application thereof | |
| CN107616985A (en) | Bacillus coagulans preparation and its application | |
| JPH11504048A (en) | Genitourinary and intestinal compositions | |
| CN108753650A (en) | Enterococcus faecium and compound micro-ecological preparation prepared therefrom | |
| CN108913638A (en) | A kind of lactobacillus acidophilus complexing agent and its preparation method and application | |
| CN108070542A (en) | A kind of high-activity bifidobacterium powder spray drying production technology and application | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN106434427A (en) | Lactic acid bacillus probiotic CGMCC NO.12421 and applicaiton to preparing lipid-lowering drugs | |
| CN115895899A (en) | Freeze-drying protective agent and freeze-drying process of fecal fungi | |
| KR20200061773A (en) | Method for culturing lactobacillus for improving cognitive ability and lactobacillus cultured by the same | |
| CN113337435A (en) | Probiotic composition and application thereof in food | |
| CN103550401B (en) | A kind of preparation method of composite microbial ecological agent effervescent tablet | |
| CN114145461B (en) | Probiotic composition for relieving nonalcoholic fatty liver | |
| CN107841463A (en) | A kind of high activity lactobacillus bacterium powder vacuum freezedrying production technology and application | |
| CN109628311A (en) | Freeze drying protectant, freeze-dried powder, capsule and preparation method thereof for protecting enterobacteriaceae | |
| CN107881133A (en) | A kind of high-activity bifidobacterium powder vacuum drying production technology and application | |
| CN116855413A (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN115044518B (en) | Liver-protecting probiotics and application thereof | |
| CN113186118B (en) | Composite probiotic preparation for improving sow productivity and preparation method thereof | |
| CN114933992A (en) | Bifidobacterium longum and application of compound preparation thereof in relieving ulcerative colitis | |
| CN103550770B (en) | Preparation method of compound effervescent tablets for treating chicken infectious bursal disease | |
| RU2273662C2 (en) | Consortium of microorganisms with probiotic effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |